Related Experiment Video
Updated: Jun 10, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Novel integrase inhibitors for HIV
Nicole Prada1, Martin Markowitz
1Aaron Diamond AIDS Research Center, 455 First Ave., 7th floor, New York, NY 10016, USA.
Expert Opinion on Investigational Drugs
|August 17, 2010
Summary
New integrase inhibitors (INIs) offer novel treatment options for HIV-1 infection. This review covers approved and investigational INIs, focusing on efficacy, safety, and resistance profiles for better patient outcomes.
Area of Science:
- Antiretroviral therapy
- HIV-1 treatment
- Integrase inhibitors
Background:
- Integrase inhibitors (INIs) are the latest class of antiretroviral agents for HIV-1.
- Raltegravir (RAL) is the only approved INI, demonstrating potency and tolerability in various patient groups.
- The development of new INIs is crucial due to the low genetic barrier for RAL resistance.
Purpose of the Study:
- To review available data on investigational integrase inhibitors.
- To focus on clinical efficacy, pharmacokinetics, safety, and resistance profiles.
- To provide an overview of INIs in clinical trials and preclinical development.
Main Methods:
- Review of clinical trial data for investigational INIs.
- Analysis of preclinical development data for novel compounds.
- Focus on elvitegravir (EVG), S/GSK1349572, S/GSK1265744, and LEDGINs.
Main Results:
- An up-to-date overview of clinically relevant INIs.
- Inclusion of promising preclinical inhibitors across all development phases.
- Comprehensive data on efficacy, safety, and resistance.
Conclusions:
- Integrase inhibitors are a vital new therapeutic class for HIV-1.
- Approved (RAL) and investigational (EVG, others) INIs offer diverse treatment options.
- This class provides valuable new choices for individuals living with HIV.
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...